NovaBridge Biosciences (NBP) Cash from Operations (2019 - 2025)

NovaBridge Biosciences (NBP) posted quarterly Cash from Operations of 14596000.0 for Q4 2025, down 33.31% year-on-year from 21886004.38 in Q4 2024, and down 893.69% on a QoQ basis from 1839000.0 in Q3 2025.

NovaBridge Biosciences (NBP) Cash from Operations (2019 - 2025) Analysis & Trends

NovaBridge Biosciences (NBP) has reported Cash from Operations for 4 consecutive years, with 14596000.0 the latest figure, recorded in Q4 2025.

  • Quarterly Cash from Operations fell 33.31% year-over-year to 14596000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 15284000.0 (down 112.72% YoY) and the FY2025 annual result came in at 20597000.0, up 60.89% from the prior year.
  • Cash from Operations slipped to 14596000.0 in Q4 2025 per NBP's latest filing, from 1839000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for NBP reached as high as 8422000.0 in Q3 2024 and fell as low as 14596000.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -19.59 Mn
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -2.49 Mn
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 201.34 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 1.43 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 1.08 Bn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -354.17 Mn
10 NovaBridge Biosciences 397.57 Mn 397.57 Mn - -14.60 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -14.60 Mn
Dec 31, 2025 -14.60 Mn
Sep 30, 2025 1.84 Mn
Sep 30, 2025 1.84 Mn
Dec 31, 2024 -10.95 Mn
Dec 31, 2024 -10.95 Mn
Sep 30, 2024 8.42 Mn
Sep 30, 2024 8.42 Mn
Dec 31, 2020 153.34 Mn
Dec 31, 2020 153.34 Mn
Dec 31, 2019 -30.64 Mn
Dec 31, 2019 -30.64 Mn